No Data
No Data
Is It a Good Idea to Invest in Stoke Therapeutics Stock Now?
H.C. Wainwright Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $35
Stoke Therapeutics' Promising Potential: Buy Rating Backed by Strong Phase 3 Trial Design and Positive Early Results
Stoke Therapeutics Analyst Ratings
Stoke Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Chardan Capital Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $24